Harvey M. Golomb to Follow-Up Studies
This is a "connection" page, showing publications Harvey M. Golomb has written about Follow-Up Studies.
Connection Strength
0.169
-
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr; 13(4):974-82.
Score: 0.020
-
Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia. 1994 Dec; 8(12):2037-40.
Score: 0.019
-
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma. 1994; 14 Suppl 1:89-93.
Score: 0.018
-
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
Score: 0.014
-
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Aug 02; 81(15):1172-4.
Score: 0.013
-
Postoperative recurrence of lung cancer: detection by whole-body gallium scintigraphy. AJR Am J Roentgenol. 1986 Nov; 147(5):911-5.
Score: 0.011
-
Chlorambucil therapy of twenty-four postsplenectomy patients with progressive hairy cell leukemia. Semin Oncol. 1984 Dec; 11(4 Suppl 2):502-8.
Score: 0.010
-
Hairy cell leukemia: a five-year update on seventy-one patients. Ann Intern Med. 1983 Oct; 99(4):485-6.
Score: 0.009
-
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 01; 96(9):2981-6.
Score: 0.007
-
Importance of substaging of stage III Hodgkin's disease. Semin Oncol. 1980 Jun; 7(2):136-43.
Score: 0.007
-
A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann Oncol. 1998 Jun; 9(6):677-80.
Score: 0.006
-
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. 1995 Jul; 9(7):1116-20.
Score: 0.005
-
Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994 May 15; 83(10):2931-8.
Score: 0.005
-
Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989 Jul 15; 40(2):171-85.
Score: 0.003
-
The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet. 1989 Jul 15; 40(2):203-16.
Score: 0.003
-
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988 Nov; 6(11):1714-21.
Score: 0.003
-
Use and prognostic value of staging mediastinoscopy in non-small-cell lung cancer. Surgery. 1987 Oct; 102(4):652-9.
Score: 0.003
-
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood. 1987 Mar; 69(3):872-7.
Score: 0.003
-
Initial alkylating agent chemotherapy in a leukemic hairy cell patient. Am J Hematol. 1984 Jan; 16(1):91-4.
Score: 0.002
-
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet. 1983 Nov; 10(3):219-36.
Score: 0.002
-
Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer. 1982 Jun 01; 49(11):2222-5.
Score: 0.002
-
Survival of patients with localized diffuse histiocytic lymphoma. Blood. 1981 Dec; 58(6):1218-23.
Score: 0.002
-
Lymphoblastic lymphoma in adults. Cancer. 1981 May 15; 47(10):2510-6.
Score: 0.002